Drugs Monitor, Page 17

(09 Dec 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 infection

December 14, 2020

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 https://doi.org/10.1056/NEJMoa2021801 An open-label, cluster-randomized trial (NCT04304053) involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome… Continue reading "(09 Dec 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 infection"

(09 Dec 2020) Favipiravir- did not seem to affect disease progression

December 14, 2020

Role of favipiravir in the treatment of adult patients with moderate to severe COVID-19: a single-center, prospective, observational, sequential cohort study from Hungary https://www.medrxiv.org/content/10.1101/2020.11.26.20238014v1 In all, 75 patients were included per cohort. In the FVP cohort, chronic heart disease (36/75,… Continue reading "(09 Dec 2020) Favipiravir- did not seem to affect disease progression"

(08 Dec 2020) Hydroxychloroquine- not found beneficial for postexposure prophylaxis

December 14, 2020

Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial https://doi.org/10.7326/M20-6519 Household-randomized, double-blind, controlled trial of hydroxychloroquine postexposure prophylaxis. (ClinicalTrials.gov: NCT04328961). SETTING: National U.S. multicenter study. PARTICIPANTS: Close contacts recently exposed (<96 hours)… Continue reading "(08 Dec 2020) Hydroxychloroquine- not found beneficial for postexposure prophylaxis"

(07 Dec 2020) Tocilizumab- reduced mortality by 14.7%

December 14, 2020

Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study https://doi.org/10.1007/s40121-020-00373-8 A multicentre retrospective cohort study (EUPAS34415) in 18 tertiary hospitals in Spain from March to April 2020. During the study… Continue reading "(07 Dec 2020) Tocilizumab- reduced mortality by 14.7%"

(06 Dec 2020) Ivermectin- 5-day course of ivermectin was found to be safe and effective

December 14, 2020

A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness https://doi.org/10.1016/j.ijid.2020.11.191 To determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients a randomized, double-blind, placebo-controlled trial of oral… Continue reading "(06 Dec 2020) Ivermectin- 5-day course of ivermectin was found to be safe and effective"

(03 Dec 2020) Solidarity trials- RDV, HCQ, LPV & IFN regimens had little or no effect on hospitalized patients with Covid-19

December 5, 2020

Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results https://doi.org/10.1056/NEJMoa2023184 At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including… Continue reading "(03 Dec 2020) Solidarity trials- RDV, HCQ, LPV & IFN regimens had little or no effect on hospitalized patients with Covid-19"

(02 Dec 2020) Itolizumab- efficiently controls immune hyperactivation

December 5, 2020

A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1 CTRI/2020/05/024959- Eligible patients were randomized (2:1) to arm A (best supportive care + Itolizumab)… Continue reading "(02 Dec 2020) Itolizumab- efficiently controls immune hyperactivation"

(01 Dec 2020) Hydroxychloroquine- HCQ+/-AZT does not facilitate virologic cure

December 5, 2020

Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 https://doi.org/10.1016/j.eclinm.2020.100645 NCT04349592 study enrolled 456 participants (152 in each of three groups: HC+AZ, HC, placebo) between 13 April and 1 August 2020. HC+AZ, HC,… Continue reading "(01 Dec 2020) Hydroxychloroquine- HCQ+/-AZT does not facilitate virologic cure"

(29 Nov 2020) Hydroxychloroquine- Zinc supplements did not enhance the clinical efficacy of HCQ

November 30, 2020

Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial https://doi.org/10.1007/s12011-020-02512-1 This was a randomized clinical trial (NCT04447534) conducted at three major University hospitals in Egypt. One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection… Continue reading "(29 Nov 2020) Hydroxychloroquine- Zinc supplements did not enhance the clinical efficacy of HCQ"

(26 Nov 2020) Favipiravir- associated with significant clinical and laboratory improvements

November 27, 2020

Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey https://doi.org/10.3906/sag-2008-33 This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. Forty patients who completed a full course (at least… Continue reading "(26 Nov 2020) Favipiravir- associated with significant clinical and laboratory improvements"